TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06422104

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: 10 Hz repetitive TMS will be delivered for 20 minutes per session and 0.7 Hz for 20 minutes per session

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: 10 Hz repetitive TMS will be delivered for 20 minutes per session and 0.7 Hz for 20 minutes per session

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: 10 Hz repetitive TMS will be delivered for 20 minutes per session and 0.7 Hz for 20 minutes per session
Study: NCT04804670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power device A
Description: Oral hygiene regimen completed daily

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power device B
Description: Oral hygiene regimen completed daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine Oral Hygiene
Description: Oral hygiene regimen completed daily
Study: NCT02997644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Education
Description: The content of the education focuses on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage.~The consent, enrollment, and video education will take about 20-30 minutes for patients in this group, and occur at the end of their preoperative visit. The patient will watch the video on a portable Tablet computer.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care Group
Description: Patients that are randomized to usual care will only receive the regular instructions about opioid usage they typically receive from their surgeon.
Study: NCT03755869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
Study: NCT02773212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-amphetamine
Description: Participants in this group will receive 60 mg of d-amphetamine daily for 4 weeks. There will be a 1 week run up dosing and a 1 week run-down medication period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Description: Participants in this group will receive 60 mg of d-amphetamine daily for 4 weeks. There will be a 1 week run up dosing and a 1 week run-down medication period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency management
Description: Contingency management is an established cocaine use disorder treatment in which individuals receive monetary rewards for abstinence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Contingency management is an established cocaine use disorder treatment in which individuals receive monetary rewards for abstinence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for d-amphetamine)
Description: 60 mg of riboflavin and cornstarch as needed.
Study: NCT01676896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma in-school class

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Day Camp

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Promotion in-school class
Study: NCT00672581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: 10mg, Oral tablet, single dose
Study: NCT02259751

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00003145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Allogeneic Lymphocytes
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02943525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vaginal packing
Description: Packing vagina with a Boric acid soaked gauze at the end of surgery
Study: NCT03803709

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inulin
Description: inulin given at different dosis from day 3 to day 20

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: maltodextrine given at different dosis from day 3 to day 20
Study: NCT02984436

Intervention type: PROCEDURE
Intervention: Blood Sample
Description: Blood samples will be collected from study participants for hs-cTnT analysis. Results of hs-cTnT will be used for research purposes only. Providers and participants will be blinded to results and participants will be treated by their healthcare providers per the standard of care.

Intervention type: BEHAVIORAL
Intervention: HEART Score
Description: The HEART Score is a prospectively studied scoring system to help emergency departments risk-stratify chest pain patients. Patients score on a scale of 0-10.
Study: NCT01021436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin inhalation solution (BAY41-6551)
Description: Daily dose of 800 mg of aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment 12 hour
Study: NCT04581005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Endurance and Resistance Exercise, Nutrition therapy, reducing intervention during the whole preoperative period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Endurance and Resistance Exercise, Nutrition therapy, reducing intervention during the whole preoperative period
Study: NCT01578707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ofatumumab
Description: The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.~Week 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity
Study: NCT02274298

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CKD feedback and tools
Description: people in the intervention arm will receive feedback on ckd quality indicators and tools to help in the detection and management of ckd
Study: NCT00623103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine capsule
Description: Rivastigmine capsules orally twice a day. Target dose 12 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch
Description: Rivastigmine patch once a day in the morning, worn for 24 hours. Target dose 10 cm\^2/day delivering 9.5 mg over a 24 hour period.
Study: NCT03353909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new crosslinked hyaluronan gel
Description: At the end of the dilatation and curettage, new crosslinked hyaluronan gel was applied to the uterine cavity.
Study: NCT02044172

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical prostatectomy
Description: radical prostatectomy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conformal radiation therapy
Description: Conformal radiation therapy, external beam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active monitoring
Description: Active monitoring of Prostate specific antigen levels and disease surveillance
Study: NCT03979248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Specified dose on specified days.
Study: NCT04039542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compassion focused therapy (CFT)
Description: Compassion focused therapy (CFT) sessions (developed from cognitive behavioural therapies) to target underlying shame and self-criticism - 10 x 90 minute sessions
Study: NCT01442909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel and pemetrexed
Description: docetaxel 60mg/m2 every 3 weeks for 4 cycles followed by pemetrexed 500mg/m2 every 3 weeks for 4 cycles; or in reverse sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel and pemetrexed
Description: docetaxel 60mg/m2 every 3 weeks for 4 cycles followed by pemetrexed 500mg/m2 every 3 weeks for 4 cycles; or in reverse sequence.
Study: NCT04371250

Intervention type: OTHER
Intervention: Survey and Questionnaire
Description: Resilience and Loneliness questionnaires
Study: NCT00672581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: 10mg, Oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: 10mg, Oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: 10mg, Oral tablet, single dose
Study: NCT04635124

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dog visit
Description: An visitor visits the participant with a dog

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dog visit
Description: An visitor visits the participant with a dog

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Encourage to engage in activity
Description: In each visit the visitor invites the participant to engage in an activitty

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Encourage to engage in activity
Description: In each visit the visitor invites the participant to engage in an activitty
Study: NCT02286570

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: videolaryngoscope used for endotracheal intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: videolaryngoscope used for endotracheal intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fastrach
Description: intubating laryngeal mask airway used for blind endotracheal intubation
Study: NCT01330394

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: transcranial Direct Current Stimulation (tDCS, 5 x 7 cm2, 1 mA, during 10 min) will be applied over the left dorsolateral prefrontal cortex once a week for 5 consecutive weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: transcranial Direct Current Stimulation (tDCS, 5 x 7 cm2, 1 mA, during 10 min) will be applied over the left dorsolateral prefrontal cortex once a week for 5 consecutive weeks.
Study: NCT04197102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD Isolate
Description: A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD isolate oil will be taken once daily for 8 weeks for participants randomized to the CBD Isolate arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CBD Broad Spectrum
Description: A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD Broad Spectrum oil will be taken once daily for 8 weeks for participants randomized to the CBD - Broad Spectrum arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: Placebo solution will be taken once daily for 8 weeks by participants randomized to the placebo arm.
Study: NCT00596128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation of SOP
Description: SOP for blood sugar monitoring and intervention will be defined and ICU nurses will be educated to use this SOP in clinical routine
Study: NCT02856607

Intervention type: OTHER
Intervention: determine the prognosis of threated patients according to the clinical care pathway.

Intervention type: OTHER
Intervention: determine the prognosis of threated patients according to the clinical care pathway.

Intervention type: OTHER
Intervention: determine the prognosis of threated patients according to the clinical care pathway.
Study: NCT05081700

Intervention type: DRUG
Intervention: All patients in the study will be treated with ocrelizumab
Description: 300 mg of OCR IV infusion will be given on Day 0 followed by a second dose of 300 mg OCR 14 days later ± 2 days, and then 600 mg of OCR as a single infusion will be given every 24 weeks thereafter per standard medical care.
Study: NCT02331550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablative treatment
Description: Use of an ablative treatment (cryotherapy) for the management of Low-Grade Squamous Intraepithelial Lesions of the cervix.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expectant management
Description: Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions were managed with observation and evaluation at 6 and 12 months after diagnosis.
Study: NCT04117672

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salovum
Description: Active egg yolk powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo egg yolk powder
Description: Normal egg yolk powder
Study: NCT01363752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: i.v. and oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: i.v. and oral
Study: NCT01985087

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Treatment of 3.4 Gy will be given daily 5 days per week over 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: During concomitant phase Temozolomide will be administered orally at 75 mg/m2 for 2 weeks concomitant with radiotherapy. During the adjuvant phase Temozolomide will be administered orally at 150 mg/m2 on days 1 through day 5 of each 28 day cycle for a maximum of 6 cycles.
Study: NCT04772196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 50,000 IU Vitamin D3 weekly for 8 weeks
Study: NCT04155541

Intervention type: DRUG
Intervention: dacomitinib hydrate
Description: The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose should be reduced appropriately according to the patient's condition.
Study: NCT04196413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GD2 CAR T cells
Description: Autologous T-Cells transduced with retroviral vector (14g2a-CD8.BB.z.iCasp9) expressing GD2-chimeric antigen receptor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 per day IV for days -4, -3, -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 500 mg/m2 per day IV for days -4, -3, -2
Study: NCT01993498

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sampling
Description: blood samples collection
Study: NCT03638284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: tDCS is a non-invasive brain stimulation that does not require general anaesthesia or surgical implantation of a device. It uses two AA size batteries to deliver direct current via rubber electrodes enclosed in saline soaked sponges.
Study: NCT02107105

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete quality of life questionnaire

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete quality of life questionnaire
Study: NCT01083888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: oral
Study: NCT00089778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 117-126:Fibroblast growth factor 5 (FGF-5)
Description: Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 117-126:Fibroblast growth factor 5 (FGF-5)
Description: Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 5 (FGF-5):172-176/217-220
Description: Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on the day after immunization and continuing for up to 4 days (a maximum of 12 doses).
Study: NCT02121015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Share

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Directed
Study: NCT02557932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard triple therapy
Description: Lansoprazole 30mg, 2 times a day + Clarithromycin 500mg, 2 times a day + Amoxicillin 1000mg, 2 times a day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth quadruple therapy
Description: Lansoprazole 30mg, 2 times a day + Bismuth 300mg, 4 times a day + Tetracycline 500mg, 4 times a day + Metronidazole 500mg, 3 times a day for 10 days
Study: NCT01646021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560 mg once daily continuous (without interruption) by mouth for 21-day cycles
Study: NCT02593305

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Super Beets Placebo
Description: Nitrate deficient beetroot powder (10g/day) for 4 weeks
Study: NCT01646021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 175 mg once daily intravenous infusion on Days 1, 8, 15 of the first cycle followed by 75 mg on Days 1, 8, 15 of each 21-day cycle
Study: NCT03065764

Intervention type: DRUG
Group type: OTHER
Intervention: 89Zr-Pembrolizumab
Description: eligible subjects will undergo two whole body immuno-PET scans with a non-therapeutic tracer dose (2 mg) of 89Zr-pembrolizumab; one with and one without a preceding cold therapeutic dose of pembrolizumab.
Study: NCT01380717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-blocker, ACE-inhibitor
Description: Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Channel Blockers, ACE-Inhibitor
Description: Calcium Channel Blockers: 5-10 mg a day. ACEi: 5-10 mg a day
Study: NCT03410407

Intervention type: OTHER
Intervention: Observation of CNS involvement
Description: AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.
Study: NCT01628653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: U-SMART
Description: 4-weeks' training
Study: NCT02893982

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: image-guided navigation of catheter placement for high dose rate (HDR) brachytherapy treatment of patients with primary liver lesions
Study: NCT03784144

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biering-Sorensen Test and Prone Plank Test
Description: All patients will be encouraged to achieve the maximum time to task failure, stopped only by muscular fatigue or pain precluding to maintain the position.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Biering-Sorensen Test and Prone Plank Test
Description: All patients will be encouraged to achieve the maximum time to task failure, stopped only by muscular fatigue or pain precluding to maintain the position.
Study: NCT04062032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: ASA 81mg taken daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: ASA 325mg taken daily
Study: NCT03760406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opti-VIM targeting in DBS surgery
Description: DBS surgery will be performed under general anaesthesia, without intra-operative clinical and electrophysiological testing, with a surgical robot and under CT-scan guidance (O-Arm ©). The VIM coordinates will be calculated with the probabilistic model that have been developed.
Study: NCT03355157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
Description: Drug intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
Description: Drug intervention
Study: NCT04507256

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: Participants randomized to AZD7442 will be administered dose 1, each in Cohort 1a (IM) and Cohort 1b (IV). Participants in Cohort 2 and 3 will receive AZD7442 (IV) doses 2 and 3, respectively. Participants in Cohort 4 will receive AZD7442 (IV) dose 4.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomised to placebo will receive the same volume of solution as participants on active treatment.